These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 11122738)

  • 1. Benefits of lipid-lowering agents in stroke and coronary heart disease: pharmacoeconomics.
    Rockson SG
    Curr Atheroscler Rep; 2000 Mar; 2(2):144-50. PubMed ID: 11122738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease.
    Hay JW; Yu WM; Ashraf T
    Pharmacoeconomics; 1999 Jan; 15(1):47-74. PubMed ID: 10345158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of intensive lipid-lowering treatment for patients with congestive heart failure and coronary heart disease in the US.
    Rosen VM; Taylor DC; Parekh H; Pandya A; Thompson D; Kuznik A; Waters DD; Drummond M; Weinstein MC
    Pharmacoeconomics; 2010; 28(1):47-60. PubMed ID: 20014876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving health outcomes without increasing costs: maximizing the full potential of lipid reduction therapy in the primary and secondary prevention of coronary heart disease.
    Jacobson TA
    Curr Opin Lipidol; 1997 Dec; 8(6):369-74. PubMed ID: 9412778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid-lowering therapy for the primary prevention of coronary heart disease.
    Gotto AM
    J Am Coll Cardiol; 1999 Jun; 33(7):2078-82. PubMed ID: 10362217
    [No Abstract]   [Full Text] [Related]  

  • 6. Statins: where are we now?
    Cowie MR
    Hosp Med; 2000 Nov; 61(11):789-92. PubMed ID: 11198749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. At what level of coronary heart disease risk should a statin be prescribed?
    Gaw A; Packard CJ
    Curr Opin Lipidol; 2000 Aug; 11(4):363-7. PubMed ID: 10945717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke.
    Heller DJ; Coxson PG; Penko J; Pletcher MJ; Goldman L; Odden MC; Kazi DS; Bibbins-Domingo K
    Circulation; 2017 Sep; 136(12):1087-1098. PubMed ID: 28687710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid-lowering for prevention of coronary heart disease: what policy now?
    Ul Haq I; Ramsay LE; Pickin DM; Yeo WW; Jackson PR; Payne JN
    Clin Sci (Lond); 1996 Oct; 91(4):399-413. PubMed ID: 8983865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of coronary heart disease prevention strategies in adults.
    Brown AD; Garber AM
    Pharmacoeconomics; 1998 Jul; 14(1):27-48. PubMed ID: 10182193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simvastatin: building on success.
    Gaw A
    Hosp Med; 2001 Jan; 62(1):29-32. PubMed ID: 11211458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simvastatin. A reappraisal of its cost effectiveness in dyslipidaemia and coronary heart disease.
    Goa KL; Barradell LB; McTavish D
    Pharmacoeconomics; 1997 Jan; 11(1):89-110. PubMed ID: 10172918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Debate: at what level of coronary heart disease risk should a statin be prescribed?
    Jackson PR; Ramsay LE
    Curr Opin Lipidol; 2000 Aug; 11(4):357-61. PubMed ID: 10945716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of statins.
    Reckless JP
    Curr Opin Lipidol; 2000 Aug; 11(4):351-6. PubMed ID: 10945715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time trend analysis and variations in prescribing lipid lowering drugs in general practice.
    Baxter C; Jones R; Corr L
    BMJ; 1998 Oct; 317(7166):1134-5. PubMed ID: 9784452
    [No Abstract]   [Full Text] [Related]  

  • 16. Economics of lipid lowering in primary prevention: lessons from the West of Scotland Coronary Prevention Study.
    Shepherd J
    Am J Cardiol; 2001 Mar; 87(5A):19B-22B. PubMed ID: 11256845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholesterol management in theory and practice.
    Gotto AM
    Circulation; 1997 Dec; 96(12):4424-30. PubMed ID: 9416913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid lowering and coronary heart disease risk: how appropriate are the national guidelines?
    Forge BH; Briganti EM
    Med J Aust; 2001 Nov; 175(9):471-5. PubMed ID: 11758075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment.
    Pickin DM; McCabe CJ; Ramsay LE; Payne N; Haq IU; Yeo WW; Jackson PR
    Heart; 1999 Sep; 82(3):325-32. PubMed ID: 10455083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.
    Jolain B; Pettitt D
    Clin Ther; 1995; 17(3):572-80. PubMed ID: 7585861
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.